Patent Troll Bill Clears House; Provisions Problematic For PhRMA Remain
This article was originally published in The Pink Sheet Daily
Executive Summary
Amendments make things a little better for drug firms as attention now shifts to the Senate version.
You may also be interested in...
Government Briefs: White House Moves On Patent Reform, DOJ Settles Endo Off-Label Complaints
Endo admits to marketing its post-herpetic neuralgia pain drug Lidoderm for unapproved uses in a $192.7 million settlement; National Economic Council Director says there is “a sweet spot for bipartisan compromise” on patent troll bills introduced in the House and Senate.
Drug Firms Ask Senate For Narrow Patent Troll Bill
“One-size-fits-all” patent troll bill will harm innovators, Johnson & Johnson’s chief IP counsel tells Senate hearing.
PTO’s New Deputy Director To Push For “Good IP Policy” Across Industries
Michelle Lee, former deputy general counsel of Google, is to lead Patent and Trademark Office until a permanent director is named; new patent reform legislation will be among her areas of focus.